Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MB-CART2019.1 in children and adolescents with relapsed or refractory mature B-cell neoplasms
NL-OMON59129Phase 2Not yet recruiting
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Nov 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zamtocabtagene autoleucel in mature B-cell neoplasm (MBCN), Burkitt lymphoma (BL), Burkitt leukemia and 4 more, sponsored by Miltenyi Biomedicine GmbH. Primary endpoints: Safety and toxicity and Best overall response rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
mature B-cell neoplasm (MBCN)Burkitt lymphoma (BL)Burkitt leukemiadiffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NL-OMON59129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59129.